Evaluating the prognostic and predictive value of the FOLR1 high-like signature and of RFC expression in large prospective cohorts of ovarian cancer patients treated with mirvetuximab soravtansine and novel strategies is warranted. Here, FOLR1 is linked to ovarian cancer.